Long‐Term Outcomes and Prognosis Factors in Patients With Idiopathic Inflammatory Myopathies Based on Myositis‐Specific Autoantibodies: A Single Cohort Study
Arthritis Care & Research · 2023-05 · 75 (5) · 1175-1182
DOI: 10.1002/acr.24993 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Arthritis Care & Research, online erschienen am 11.12.2022. Verfasst von Wei Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: China-Japan Friendship Hospital, Beijing, China. Hauptthemen laut MEDLINE: Myositis, Lung Diseases, Interstitial. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Beijing Municipal Science and Technology Commission.
Abstract (Originalsprache)
Objective
This study was undertaken to investigate the long‐term survival rates and prognostic factors in patients with idiopathic inflammatory myopathies (IIMs) based on myositis‐specific antibody (MSA) stratification.
Methods
Exactly 628 patients with an IIM were included. Kaplan‐Meier survival curves, univariate, and multivariate Cox regression were used to analyze the outcomes and risk factors.
Results
The cumulative 1‐, 5‐, and 10‐year survival rates for IIM patients overall were 91.4%, 82.8%, and 75.6%, respectively. The survival rate in the MSA subset was significantly different ( P < 0.001). The 1‐ and 10‐year survival rates in the anti–melanoma differentiation–associated protein 5 (anti–MDA‐5)–positive subgroup were 79.5% and 58.5%, respectively, which were the lowest among all subgroups. The 10‐year survival rate of anti–signal recognition particle (anti‐SRP)–positive patients was the highest (96.4%). Independent risk factors that impacted the long‐term prognosis for IIM patients included rapidly progressive interstitial lung disease (RP‐ILD), malignancy, and elevated serum ferritin levels (hazard ratio [HR] 17.47, 20.36, and 9.15, respectively, P < 0.01), whereas disease duration was a protective factor (HR 0.27, P = 0.003). Among these subsets, the strongest independent risk factor for death in the anti–MDA‐5–positive subgroup was RP‐ILD (HR 3.4, P = 0.017). Malignancy was an independent risk factor in the anti–aminoacyl‐tRNA synthetase antibody–positive, anti–transcription intermediary factor 1γ–positive, and MSA‐negative subgroups (HR 46.69, 6.65, and 4.48, respectively; P < 0.001). RP‐ILD was also a risk factor in the prognosis of individuals in the MSA‐negative subgroup (HR 72.28, P < 0.001).
Conclusion
Despite favorable overall survival in patients with IIM, the anti–MDA‐5–positive subgroup had the highest mortality rate among all MSA subgroups, highlighting the distinctive prognosis for patients with different MSAs. RP‐ILD and malignancy are the most common causes of death in IIM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- China-Japan Friendship Hospital, Beijing, China.
ORCID-Profile: Wei Jiang, Hanbo Yang, Qinglin Peng
Förderung
- Beijing Municipal Science and Technology Commission
Zitieren
APA
Jiang, W., Shi, J., Yang, H., Tian, X., Yang, H., Chen, Q., Zhang, L., Peng, Q., Wang, G., & Lu, X. (2023). Long‐Term Outcomes and Prognosis Factors in Patients With Idiopathic Inflammatory Myopathies Based on Myositis‐Specific Autoantibodies: A Single Cohort Study. Arthritis Care & Research, 75(5), 1175-1182. https://doi.org/10.1002/acr.24993
Vancouver
Jiang W, Shi J, Yang H, Tian X, Yang H, Chen Q, et al. Long‐Term Outcomes and Prognosis Factors in Patients With Idiopathic Inflammatory Myopathies Based on Myositis‐Specific Autoantibodies: A Single Cohort Study. Arthritis Care & Research. 2023;75(5):1175-1182. doi:10.1002/acr.24993
BibTeX
@article{Jiang2023,
author = {Jiang, Wei and Shi, Jingli and Yang, Hongxia and Tian, Xiaolan and Yang, Hanbo and Chen, Qingning and Zhang, Lining and Peng, Qinglin and Wang, Guochun and Lu, Xin},
title = {Long‐Term Outcomes and Prognosis Factors in Patients With Idiopathic Inflammatory Myopathies Based on Myositis‐Specific Autoantibodies: A Single Cohort Study},
journal = {Arthritis Care & Research},
year = {2023},
volume = {75},
number = {5},
pages = {1175--1182},
doi = {10.1002/acr.24993}
}
EUVIMED